These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

493 related items for PubMed ID: 26286966

  • 1. CLM29 and CLM24, pyrazolopyrimidine derivatives, have antitumoral activity in vitro in anaplastic thyroid cancer, with or without BRAF mutation.
    Fallahi P, Ferrari SM, La Motta C, Materazzi G, Bocci G, Da Settimo F, Miccoli P, Antonelli A.
    Endocrine; 2016 Jul; 53(1):136-44. PubMed ID: 26286966
    [Abstract] [Full Text] [Related]

  • 2. Novel pyrazolopyrimidine derivatives as tyrosine kinase inhibitors with antitumoral activity in vitro and in vivo in papillary dedifferentiated thyroid cancer.
    Antonelli A, Bocci G, La Motta C, Ferrari SM, Fallahi P, Fioravanti A, Sartini S, Minuto M, Piaggi S, Corti A, Alì G, Berti P, Fontanini G, Danesi R, Da Settimo F, Miccoli P.
    J Clin Endocrinol Metab; 2011 Feb; 96(2):E288-96. PubMed ID: 21147882
    [Abstract] [Full Text] [Related]

  • 3. CLM3, a multitarget tyrosine kinase inhibitor with antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo.
    Antonelli A, Bocci G, Fallahi P, La Motta C, Ferrari SM, Mancusi C, Fioravanti A, Di Desidero T, Sartini S, Corti A, Piaggi S, Materazzi G, Spinelli C, Fontanini G, Danesi R, Da Settimo F, Miccoli P.
    J Clin Endocrinol Metab; 2014 Apr; 99(4):E572-81. PubMed ID: 24423321
    [Abstract] [Full Text] [Related]

  • 4. Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo.
    Ferrari SM, Bocci G, Di Desidero T, Elia G, Ruffilli I, Ragusa F, Orlandi P, Paparo SR, Patrizio A, Piaggi S, La Motta C, Ulisse S, Baldini E, Materazzi G, Miccoli P, Antonelli A, Fallahi P.
    Oncol Rep; 2018 May; 39(5):2225-2234. PubMed ID: 29517103
    [Abstract] [Full Text] [Related]

  • 5. CLM29, a multi-target pyrazolopyrimidine derivative, has anti-neoplastic activity in medullary thyroid cancer in vitro and in vivo.
    Antonelli A, Bocci G, La Motta C, Ferrari SM, Fallahi P, Corrado A, Fioravanti A, Sartini S, Orlandi P, Piaggi S, Corti A, Materazzi G, Galleri D, Ulisse S, Fontanini G, Danesi R, Da Settimo F, Miccoli P.
    Mol Cell Endocrinol; 2014 Aug 05; 393(1-2):56-64. PubMed ID: 24931161
    [Abstract] [Full Text] [Related]

  • 6. Combination BRAFV600E Inhibition with the Multitargeting Tyrosine Kinase Inhibitor Axitinib Shows Additive Anticancer Activity in BRAFV600E-Mutant Anaplastic Thyroid Cancer.
    Gunda V, Ghosh C, Hu J, Zhang L, Zhang YQ, Shen M, Kebebew E.
    Thyroid; 2023 Oct 05; 33(10):1201-1214. PubMed ID: 37675898
    [Abstract] [Full Text] [Related]

  • 7. Vandetanib has antineoplastic activity in anaplastic thyroid cancer, in vitro and in vivo.
    Ferrari SM, Bocci G, Di Desidero T, Ruffilli I, Elia G, Ragusa F, Fioravanti A, Orlandi P, Paparo SR, Patrizio A, Piaggi S, La Motta C, Ulisse S, Baldini E, Materazzi G, Miccoli P, Antonelli A, Fallahi P.
    Oncol Rep; 2018 May 05; 39(5):2306-2314. PubMed ID: 29517106
    [Abstract] [Full Text] [Related]

  • 8. CLM94, a novel cyclic amide with anti-VEGFR-2 and antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo.
    Antonelli A, Bocci G, La Motta C, Ferrari SM, Fallahi P, Ruffilli I, Di Domenicantonio A, Fioravanti A, Sartini S, Minuto M, Piaggi S, Corti A, Alì G, Di Desidero T, Berti P, Fontanini G, Danesi R, Da Settimo F, Miccoli P.
    J Clin Endocrinol Metab; 2012 Apr 05; 97(4):E528-36. PubMed ID: 22278419
    [Abstract] [Full Text] [Related]

  • 9. Sorafenib inhibits vascular endothelial cell proliferation stimulated by anaplastic thyroid cancer cells regardless of BRAF mutation status.
    Ishihara S, Onoda N, Noda S, Asano Y, Tauchi Y, Morisaki T, Kashiwagi S, Takashima T, Ohira M.
    Int J Oncol; 2019 Nov 05; 55(5):1069-1076. PubMed ID: 31545405
    [Abstract] [Full Text] [Related]

  • 10. Torin2 targets dysregulated pathways in anaplastic thyroid cancer and inhibits tumor growth and metastasis.
    Sadowski SM, Boufraqech M, Zhang L, Mehta A, Kapur P, Zhang Y, Li Z, Shen M, Kebebew E.
    Oncotarget; 2015 Jul 20; 6(20):18038-49. PubMed ID: 25945839
    [Abstract] [Full Text] [Related]

  • 11. Genomic Alterations of Anaplastic Thyroid Carcinoma Detected by Targeted Massive Parallel Sequencing in a BRAF(V600E) Mutation-Prevalent Area.
    Jeon MJ, Chun SM, Kim D, Kwon H, Jang EK, Kim TY, Kim WB, Shong YK, Jang SJ, Song DE, Kim WG.
    Thyroid; 2016 May 20; 26(5):683-90. PubMed ID: 26980298
    [Abstract] [Full Text] [Related]

  • 12. BRAF Inhibition in BRAFV600E-Positive Anaplastic Thyroid Carcinoma.
    Lim AM, Taylor GR, Fellowes A, Cameron L, Lee B, Hicks RJ, McArthur GA, Angel C, Solomon B, Rischin D.
    J Natl Compr Canc Netw; 2016 Mar 20; 14(3):249-54. PubMed ID: 26957611
    [Abstract] [Full Text] [Related]

  • 13. Expression of angiogenic switch, cachexia and inflammation factors at the crossroad in undifferentiated thyroid carcinoma with BRAF(V600E).
    Husain A, Hu N, Sadow PM, Nucera C.
    Cancer Lett; 2016 Oct 01; 380(2):577-585. PubMed ID: 26189429
    [Abstract] [Full Text] [Related]

  • 14. Differential effects of MAPK pathway inhibitors on migration and invasiveness of BRAF(V600E) mutant thyroid cancer cells in 2D and 3D culture.
    Ingeson-Carlsson C, Martinez-Monleon A, Nilsson M.
    Exp Cell Res; 2015 Nov 01; 338(2):127-35. PubMed ID: 26384551
    [Abstract] [Full Text] [Related]

  • 15. PP121, a dual inhibitor of tyrosine and phosphoinositide kinases, inhibits anaplastic thyroid carcinoma cell proliferation and migration.
    Che HY, Guo HY, Si XW, You QY, Lou WY.
    Tumour Biol; 2014 Sep 01; 35(9):8659-64. PubMed ID: 24867098
    [Abstract] [Full Text] [Related]

  • 16. Neoadjuvant treatment with lenvatinib and pembrolizumab in a BRAF V600E-mutated anaplastic thyroid cancer: a case report.
    Barbaro D, Forleo R, Profilo MA, Lapi P, Giani C, Torregrossa L, Macerola E, Materazzi G.
    Front Endocrinol (Lausanne); 2024 Sep 01; 15():1389294. PubMed ID: 39045273
    [Abstract] [Full Text] [Related]

  • 17. Dissecting Anaplastic Thyroid Carcinoma: A Comprehensive Clinical, Histologic, Immunophenotypic, and Molecular Study of 360 Cases.
    Xu B, Fuchs T, Dogan S, Landa I, Katabi N, Fagin JA, Tuttle RM, Sherman E, Gill AJ, Ghossein R.
    Thyroid; 2020 Oct 01; 30(10):1505-1517. PubMed ID: 32284020
    [Abstract] [Full Text] [Related]

  • 18. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
    Quiros RM, Ding HG, Gattuso P, Prinz RA, Xu X.
    Cancer; 2005 Jun 01; 103(11):2261-8. PubMed ID: 15880523
    [Abstract] [Full Text] [Related]

  • 19. Antineoplastic Effect of ALK Inhibitor Crizotinib in Primary Human Anaplastic Thyroid Cancer Cells with STRN-ALK Fusion In Vitro.
    Ferrari SM, Ragusa F, Elia G, Mazzi V, Balestri E, Botrini C, Rugani L, Patrizio A, Piaggi S, La Motta C, Ulisse S, Virili C, Antonelli A, Fallahi P.
    Int J Mol Sci; 2024 Jun 19; 25(12):. PubMed ID: 38928438
    [Abstract] [Full Text] [Related]

  • 20. Signal transducer and activator of transcription 3 inhibition alleviates resistance to BRAF inhibition in anaplastic thyroid cancer.
    Wang Y, Hu Z, Ma W, Niu Y, Su J, Zhang L, Zhao P.
    Invest New Drugs; 2021 Jun 19; 39(3):764-774. PubMed ID: 33245464
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.